Kathryn Kwant

Kathryn has 12 years of experience engineering proteins for improved properties. She spent 5 years as a key early scientist at Harpoon Therapeutics, where she developed bispecific immunotherapies and protease activated immunotherapies. She has helped develop multiple drugs that are currently in the clinic to treat various cancers and has multiple patents and patent applications.